Shots:
- Prestige Biopharma has entered into an exclusive license & supply agreement with Biosidus to commercialize Tuznue, a biosimilar version of Herceptin (trastuzumab) across Latin American markets, incl. Argentina, Mexico, Bolivia, & Paraguay
- As per the deal, Biosidus gains exclusive rights to market & distribute Tuznue in Argentina, Mexico, Bolivia & Paraguay, while Prestige Biopharma will be responsible for production & supply of the drug substance, with Biosidus manufacturing the drug product at its facility in Buenos Aires
- Prestige secured EC approval for Tuznue in Sep 2024 for the treatment of HER2+ metastatic & early breast cancer, as well as HER2+ metastatic gastric cancer
Ref: PRNewswire | Image: Prestige Biopharma and Biosidus | Press Release
Related News: Teva and Prestige Biopharma Sign a Licensing Agreement to Commercialize Tuznue (Biosimilar, Herceptin) Across EU
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
